We have located links that may give you full text access.
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Duration of preoperative β-blockade and outcomes after major elective noncardiac surgery.
Canadian Journal of Cardiology 2014 Februrary
BACKGROUND: Although practice guidelines recommend that perioperative β-blockade be initiated at least several days to weeks before noncardiac surgery is performed, the minimum required period of preoperative therapy is unclear.
METHODS: Population-based administrative databases were used to conduct a cohort study of 48,103 patients aged ≥ 66 years who underwent major elective noncardiac surgery in Ontario, Canada and received preoperative β-blocker therapy. We used multivariable logistic regression to determine the association of duration of preoperative β-blocker treatment (classified as 1-7 days, 8-30 days, and ≥ 31 days) with 30-day mortality, 30-day myocardial infarction (MI), 30-day ischemic stroke, and 1-year mortality.
RESULTS: The duration of preoperative β-blocker treatment was 1-7 days in 1105 patients (2.3%), 8-30 days in 2639 patients (5.5%), and ≥ 31 days in 44,269 patients (92.0%). Compared with ≥ 31 days of preoperative therapy, 1-7 days of therapy was associated with increased 30-day mortality (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.03-2.16; P = 0.03], whereas 8-30 days of therapy was not (OR, 0.95; 95% CI, 0.69-1.31; P = 0.77). One to 7 days of preoperative therapy was not significantly associated with 1-year mortality (OR, 1.06; 95% CI, 0.84-1.35; P = 0.62), 30-day MI (OR, 1.26; 95% CI, 0.92-1.71; P = 0.15), or 30-day ischemic stroke (OR, 1.37; 95% CI, 0.64-2.94; P = 0.41).
CONCLUSIONS: Initiation of β-blocker therapy 1-7 days before noncardiac surgery is associated with increased 30-day mortality. The findings merit further evaluation by randomized trials.
METHODS: Population-based administrative databases were used to conduct a cohort study of 48,103 patients aged ≥ 66 years who underwent major elective noncardiac surgery in Ontario, Canada and received preoperative β-blocker therapy. We used multivariable logistic regression to determine the association of duration of preoperative β-blocker treatment (classified as 1-7 days, 8-30 days, and ≥ 31 days) with 30-day mortality, 30-day myocardial infarction (MI), 30-day ischemic stroke, and 1-year mortality.
RESULTS: The duration of preoperative β-blocker treatment was 1-7 days in 1105 patients (2.3%), 8-30 days in 2639 patients (5.5%), and ≥ 31 days in 44,269 patients (92.0%). Compared with ≥ 31 days of preoperative therapy, 1-7 days of therapy was associated with increased 30-day mortality (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.03-2.16; P = 0.03], whereas 8-30 days of therapy was not (OR, 0.95; 95% CI, 0.69-1.31; P = 0.77). One to 7 days of preoperative therapy was not significantly associated with 1-year mortality (OR, 1.06; 95% CI, 0.84-1.35; P = 0.62), 30-day MI (OR, 1.26; 95% CI, 0.92-1.71; P = 0.15), or 30-day ischemic stroke (OR, 1.37; 95% CI, 0.64-2.94; P = 0.41).
CONCLUSIONS: Initiation of β-blocker therapy 1-7 days before noncardiac surgery is associated with increased 30-day mortality. The findings merit further evaluation by randomized trials.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app